Zobrazeno 1 - 10
of 127
pro vyhledávání: '"Amy O. Johnson"'
Autor:
Ronald M. Krauss, Kathleen Wojnooski, Joseph Orr, J. Casey Geaney, Cathy Anne Pinto, Yang Liu, John A. Wagner, Julie Mabalot Luk, Amy O. Johnson-Levonas, Matt S. Anderson, Hayes M. Dansky
Publikováno v:
Journal of Lipid Research, Vol 53, Iss 3, Pp 540-547 (2012)
We investigated the effects of the cholesteryl ester (CE) transfer protein inhibitor anacetrapib (ANA) on plasma lipids, lipoprotein subfraction concentrations, and lipoprotein composition in 30 healthy individuals. Participants (n = 30) were randomi
Externí odkaz:
https://doaj.org/article/e73cb9fd0bf443d08fd974d0c9fce2b6
Autor:
Patricia Jumes, Yang Liu, Thomas P. Roddy, Rajasekhar Ramakrishnan, Wahida Karmally, Gissette Reyes-Soffer, David E. Gutstein, Haihong Zhou, Stephen Holleran, John A. Wagner, Santica M. Marcovina, Amy O. Johnson-Levonas, John S. Millar, Daniel J. Rader, Brian K. Hubbard, Stephen F. Previs, Tiffany Thomas, Henry N. Ginsberg
Publikováno v:
Arteriosclerosis, Thrombosis, and Vascular Biology
Supplemental Digital Content is available in the text.
Objective— Lp(a) [lipoprotein (a)] is composed of apoB (apolipoprotein B) and apo(a) [apolipoprotein (a)] and is an independent risk factor for cardiovascular disease and aortic stenosis.
Objective— Lp(a) [lipoprotein (a)] is composed of apoB (apolipoprotein B) and apo(a) [apolipoprotein (a)] and is an independent risk factor for cardiovascular disease and aortic stenosis.
Autor:
Hidenori Arai, Tamio Teramoto, Robert O. Blaustein, Mariko Nakagomi, Katsunori Ikewaki, Hiroyuki Daida, Hirotaka Numaguchi, Masayoshi Shirakawa, Yuichiro Watanabe, Amy O. Johnson-Levonas, Taro Kakikawa, Yuko Maeda
Publikováno v:
Atherosclerosis. 261:69-77
We aimed to assess the effects of cholesteryl ester transfer protein inhibitor anacetrapib added to statin ± other lipid-modifying therapies (LMT) in Japanese patients with dyslipidemia who were not at their LDL-C goal.Patients on a stable dose of s
Autor:
Clayton D. Knox, Amit Mahipal, Heather Hirsch, Neeta Somaiah, Andrew J. Wagner, Amy O. Johnson-Levonas, Giuseppe Russo, David S. Hong, Raymond L. H. Lam, Shelonitda Rose, Udai Banerji, Craig Fancourt, Amy Meister
Publikováno v:
Journal of Clinical Oncology. 35:1304-1311
Purpose To evaluate MK-8242 in patients with wild-type TP53 advanced solid tumors. Patients and Methods MK-8242 was administered orally twice a day on days 1 to 7 in 21-day cycles. The recommended phase II dose (RP2D) was determined on the basis of s
Autor:
Carol Addy, Ashley Martucci, Marleen Depré, J. N. de Hoon, Joanna Z. Peng, John A. Wagner, Amy O. Johnson-Levonas, I.N. Gendrano, Rajesh Krishna, S. Aubrey Stoch, Wouter Haazen, Martine Robberechts, Xiaoli S. Glasgow, Daniel Tatosian
Publikováno v:
Journal of Clinical Pharmacology
The pharmacokinetics (PK), and pharmacodynamics (PD) of omarigliptin, a novel once-weekly DPP-4 inhibitor, were assessed following single and multiple doses in healthy subjects. Absorption was rapid and food did not influence single dose PK. Accumula
Autor:
Mariko Nakagomi, Hidenori Arai, Hiroyuki Daida, Masayoshi Shirakawa, Hirotaka Numaguchi, Sanskruti Vaidya, Taro Kakikawa, Yuko Maeda, Amy O. Johnson-Levonas, Tamio Teramoto, Katsunori Ikewaki, Robert O. Blaustein
Publikováno v:
Atherosclerosis. 249:215-223
This multicenter, randomized, double-blind, placebo-controlled study assessed the lipid-modifying efficacy/safety profile of anacetrapib 100 mg added to ongoing statin ± other lipid-modifying therapies (LMT) in Japanese patients with heterozygous fa
Autor:
Patricia Jumes, Rajasekhar Ramakrishnan, Stephen Holleran, John S. Millar, Gissette Reyes-Soffer, Amanda Baer, Yang Liu, Henry N. Ginsberg, Tiffany Thomas, David E. Gutstein, John A. Wagner, Amy O. Johnson-Levonas, Richard L. Dunbar, Emil M. deGoma, Daniel J. Rader, Michael E. Lassman, Wahida Karmally, Colleen Ngai, Ellie Coromilas, Hashmi Rafeek, Daniel S. Donovan, Bela F. Asztalos
Publikováno v:
Arteriosclerosis, Thrombosis, and Vascular Biology. 36:994-1002
Objective— Anacetrapib (ANA), an inhibitor of cholesteryl ester transfer protein (CETP) activity, increases plasma concentrations of high-density lipoprotein cholesterol (HDL-C), apolipoprotein A-I (apoA)-I, apoA-II, and CETP. The mechanisms respon
Autor:
Laura George, Bruce DeGroot, Dennis Swearingen, Xiaoli S. Glasgow, Daniel Tatosian, Eunkyung Kauh, Amy O. Johnson-Levonas, Katherine Dunnington, Nadia Cardillo Marricco, I.N. Gendrano
Publikováno v:
Clinical Pharmacology in Drug Development. 5:383-392
Omarigliptin is a dipeptidyl peptidase-4 inhibitor being developed as a once-weekly treatment for type 2 diabetes. This double-blind, double-dummy, randomized, 3-period balanced crossover study definitively evaluated the effects of a supratherapeutic
Autor:
Annelieke C. Kruithof, Sandra A.G. Visser, Huub-Jan Kleijn, Jacobus Burggraaf, Pieter-Jan de Kam, Amy O. Johnson-Levonas, Marie-José van Lierop, Rik de Greef, Rolien Bosch
Publikováno v:
European Journal of Pharmaceutical Sciences. 84:9-17
Exposure-response analyses of sugammadex on activated partial thromboplastin time (APTT) and prothrombin time international normalized ratio (PT(INR)) were performed using data from two clinical trials in which subjects were co-treated with anti-coag
Autor:
Carol Addy, Catherine Z. Matthews, I.N. Gendrano, Eunkyung Kauh, John A. Wagner, Diana Selverian, Ashley Martucci, S. Aubrey Stoch, Xiaoli S. Glasgow, Marie Gutierrez, Amy O. Johnson-Levonas, Daniel Tatosian
Publikováno v:
Clinical Therapeutics. 38:516-530
Purpose Omarigliptin (MK-3102) is a potent, oral, long-acting dipeptidyl peptidase (DPP)-4 inhibitor approved in Japan and in global development as a once-weekly treatment for type 2 diabetes mellitus (T2DM). The aim of this study was to investigate